CORT
Corcept Therapeutics Incorporated
CORT's outlook is improving despite an expensive valuation.
LLY
Eli Lilly and Company
LLY has the edge over CORT overall, supported by stronger valuation and lower modeled downside.
CORT Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
CORT's revenue, profitability, cash flow and balance sheet are all currently strong.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CORT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 17x | $73.71 | — |
| Cheap | 22x | $27.59 | -63% |
| Fair | 29x | $36.55 | -50% |
| Current | 58x | $73.71 | — |
| Expensive | 59x | $75.21 | +2% |
Historical ranges are pointers, not guarantees.
CORT's PE is in its expensive range at 58x. If earnings grow as analysts expect, today's price would be 17x next year's earnings, in its cheap range.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over CORT in the historical PE scenario, which offers more potential upside but is not a forecast.
CORT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for CORT, with profitability improving. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CORT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.42 | +248% |
| Q3 2026 | $1.27 | +46% |
| Q2 2026 | $0.42 | -63% |
| Q1 2026 | $0.35 | -70% |
| Q4 2025 | $0.82 | -33% |
| Q3 2025 | $0.87 | -30% |
| Q2 2025 | $1.12 | 0% |
| Q1 2025 | $1.15 | +9.5% |
| Q4 2024 | $1.23 | +31% |
CORT earned $1.27 per share over the past year, up 46% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CORT on earnings, with more consistent year-over-year improvement.
CORT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $340.5M | +64% |
| Q2 2026 | $256.1M | +32% |
| Q1 2026 | $164.9M | +4.9% |
| Q4 2025 | $202.1M | +11% |
| Q3 2025 | $207.6M | +14% |
| Q2 2025 | $194.4M | +19% |
| Q1 2025 | $157.2M | +7.1% |
| Q4 2024 | $181.9M | +34% |
CORT's revenue has grown year over year for 22 quarters in a row: $340M last quarter, up 64% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | +29 points |
| Q2 2026 | 16% | +2.4 points |
| Q1 2026 | -30% | -32 points |
| Q4 2025 | 2.2% | -12 points |
| Q3 2025 | 4.9% | -21 points |
| Q2 2025 | 14% | -8 points |
| Q1 2025 | 2.2% | -18 points |
| Q4 2024 | 14% | -9.5 points |
CORT's operating margin was 34% last quarter, up 29 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CORT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CORT on profitability, with a higher operating margin.
CORT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $142.2M | +161% |
| Q2 2026 | $31M | -29% |
| Q1 2026 | -$17M | -438% |
| Q4 2025 | $38.4M | -35% |
| Q3 2025 | $54.5M | -25% |
| Q1 2025 | $5M | -79% |
| Q4 2024 | $59.2M | +905% |
| Q3 2024 | $72.2M | +37% |
CORT generated $195M in free cash flow over the past year, up 20% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CORT on cash flow, with more consistent year-over-year improvement.
CORT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +4.8M shares |
| 1 year | +3.1% | +3.8M shares |
| 3 years | +11% | +12.1M shares |
| 5 years | -1.5% | -1.9M shares |
| Available history | +0.5% | +635K shares |
CORT has 123M diluted shares, up 3.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5.7M |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $42.5M |
| Q2 2025 | $103M |
| Q1 2025 | $27.4M |
| Q4 2024 | — |
CORT has spent almost nothing on buybacks in the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CORT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CORT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -13.2x | Net Cash |
| Q4 2025 | -2.6x | Net Cash |
| Q3 2025 | -1.9x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -0.8x | Net Cash |
| Q4 2024 | -0.9x | Net Cash |
| Q3 2024 | -1.0x | Net Cash |
CORT has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CORT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.9 | Neutral |
| Stochastic | 3.4 | Oversold |
CORT's weekly RSI is 39 (neutral) and its Stochastic is 3 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CORT PE vs Healthcare Sector
| Metric | CORT | Sector median | Relative |
|---|---|---|---|
| PE | 58x | 26x | 125% above |
| PE % | 82 | 29 | 53 pts above |
CORT is trading at 58x earnings, a 125% premium to the Healthcare sector's median of 26x.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over CORT on valuation relative to its sector.
CORT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $97.1 | 24% below |
| 20 week MA | $102.8 | 28% below |
| 50 week MA | $73.4 | 0.4% above |
| 100 week MA | $71.2 | 3.6% above |
| 200 week MA | $50.5 | 46% above |
CORT has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 46% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CORT on trend strength, trading above more of its moving averages.
CORT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.3 | $27.2 | +121% |
| 2021 | $27.2 | $19.9 | -27% |
| 2022 | $19.9 | $20.7 | +4% |
| 2023 | $20.7 | $32.5 | +57% |
| 2024 | $32.5 | $52.5 | +62% |
| 2025 | $52.5 | $82.7 | +58% |
| 2026 YTD | $82.7 | $73.7 | -11% |
CORT has finished higher in five of the last six years, four of them by more than 50%. It's down 11% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CORT on returns for 2026, with the stronger performance.